Table 3.
Calculation of the score and cutoff points of the prognostic groups.
| Parameter | Value | Points | ||
|---|---|---|---|---|
| HR | Negative | 6 | ||
| HER2 | Negative | 5 | ||
| MFI ≤ 24 | ≤24 | 9 | ||
| MFI > 24 | >24 | 5 | ||
| Brain metastases | Yes | 6 | ||
| Lung metastases | Yes | 3 | ||
| Bone metastases | Yes | 3 | ||
| Total bilirubin | >1.5 ULN | 8 | ||
| LDH | >250 U/L | 5 | ||
| GAR | >1.5 | 4 | ||
| For all other values | 0 | |||
| Points | Prognostic groups | 2-year survival | 3-year survival | Median overall survival, months |
| <16 | Low risk | 70% | 54% | 39.97 (33.59–46.35) |
| 16–25 | Intermediate risk | 44% | 25% | 21.03 (18.44–23.62) |
| >25 | High risk | 6% | 1% | 8.80 (6.78–10.82) |
HR, hormone receptor; HER2, human epidermal growth factor receptor 2; MFI: metastasis-free interval; LDH, lactate dehydrogenase; GAR, γ-glutamyl transferase-to-albumin ratio.